STUDY

GALAXY™ PROGRAM OUTCOME STUDIES

Other patient groups identified as being at increased risk for cardiovascular disease include:

  • Low LDL-C but elevated C-reactive protein (CRP) levels1
  • End-stage renal disease2
  • Chronic heart failure3

The GALAXY outcome studies will provide the first prospective data on the efficacy of statin therapy in these patient groups4

References:
1-1Ridker P. Circulation 2003; 108: 2292–2297; 2- US Renal Data System. NIH, National Institute of Diabetes and Digestive and Kidney Diseases 2002 Annual Data Report; 3-Fonarow GC, Horwich TB. RevCardiovasc Med 2003; 4: 8–17; 4-Schuster H. Expert Rev Cardiovasc Ther 2007;5(2):177–193
arrow gris

Estudios completados de resultados GALAXY (1) y (2)

GALAXY OUTCOME STUDIESCOMPLETED (2)

Jupiter

JUPITER

arrow dorado
JupiterJUPITER

GALAXY OUTCOME STUDIES COMPLETED (1)

A long-term, randomized, double-blind, placebo-controlled study to evaluate CRESTOR® 20 mg in the primary prevention of cardiovascular events in 15,000 subjects with low LDL-C levels and elevated CRP levels*1-6

arrow abajo
Corona

CORONA

arrow dorado
CoronaCORONA

GALAXY OUTCOME STUDIES COMPLETED (1)

A long-term, randomized, double-blind, placebo-controlled study to evaluate CRESTOR® 10 mg on cardiovascular mortality and morbidity and overall survival in 5016 patients with symptomatic chronic systolic heart failure (NYHA II-IV) of ischemic etiology who received standard treatment7-11

arrow abajo
Aurora

AURORA

arrow dorado
AuroraAURORA

GALAXY OUTCOME STUDIES COMPLETED (2)

Long-term, randomized, double-blind, placebo-controlled study to evaluate the effects of CRESTOR® 10 mg on survival and major cardiovascular events in 2775 subjects with end-stage renal disease on chronic hemodialysis12-15

arrow abajo

CRESTOR® GALAXY PROGRAM SUMMARY

A large, comprehensive, long-term, and evolving global research initiative.

It will build on the success of the statin class and address important unanswered questions in statin research

Focuses on reducing cardiovascular risk and improving patient outcomes

Additional studies will be added as clinical development of CRESTOR® continues

Currently, 24 studies involving >65,000 participants in >55 countries have been completed.

References:
1- Ridker P. Circulation 2003;108:2292–2297; 2- Ridker P et al. Am J Cardiol 2007;100(11):1659–1664; 3- Ridker P et al. N Engl J Med 2008;359(21):2195–2207; 4- Glynn RJ et al. Clin Chem 2008;55:305–312;5- Glynn RJ et al. N Engl J Med 2009; doi:10.1056/nejmoa0900241; 6- Ridker P et al. Lancet 2009;373(9670):1175–1182; 7- Kjekshus J et al. Eur J Heart Failure 2005;7:1059–1069; 8- Kjekshus J et al. N Engl JMed 2007;357 (22):2248–2261; 9- Clearfield M et al. Curr Atheroscler Rep 2009;11(1):5–6,8; 10- Waagstein F et al. J Am Coll Cardiol 2009;53:A153,1015–205; 11- McMurray JJV et al. J Am Coll Cardiol2009;53:A165,1033–165; 12- Fellström B et al. Curr Control Trials Cardiovasc Med 2005;6(1):9; 13- Fellström B et al. Atheroscler Suppl 2006;7:578Abs Th-P16:387; 14- Fellström B et al. Kidney Blood Press Res 2007;30:314–322; 15- Fellström B et al. N Engl J Med 2009; 360(14):1395–1407.*Following a recommendation from the Independent Data Monitoring Board the study was stopped early (29 March 2008). CRP= Proteina C-reactiva

Exclusive material for health professionals. Produced by AstraZeneca CAMCAR Costa Rica S.A., Roble Corporate Center, 5th floor, Escazú, San José Costa Rica,phone: (506) 2201-3400, P.O. Box: 993-1260 Escazú. www.camcar.astrazeneca.com for AstraZeneca CAMCAR S.A. To report an adverse event, quality complaints ormedical information, visit: https://www.contactazmedical.astrazeneca.com CC-11139/November 2025